Comparative Pharmacology
Head-to-head clinical analysis: GANTANOL versus MICROSUL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GANTANOL versus MICROSUL.
GANTANOL vs MICROSUL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfamethoxazole is a sulfonamide that inhibits bacterial dihydropteroate synthase, preventing folate synthesis. Trimethoprim inhibits bacterial dihydrofolate reductase, blocking tetrahydrofolate production. The combination produces sequential blockade of folate metabolism, leading to bactericidal activity.
MICROSUL inhibits bacterial dihydropteroate synthase, preventing folate synthesis, and also acts as a competitive antagonist of para-aminobenzoic acid (PABA).
800 mg orally every 12 hours for 5-7 days.
Adult: 160 mg/800 mg (trimethoprim/sulfamethoxazole) orally every 12 hours for 14 days; intravenous dosing: 8-10 mg/kg/day (as trimethoprim) divided every 6, 8, or 12 hours.
None Documented
None Documented
Terminal elimination half-life: 8-12 hours in healthy adults; prolonged in renal impairment (up to 24-36 hours in CrCl <30 mL/min).
Terminal elimination half-life: 24-36 hours; prolonged in renal impairment
Renal: 70% as unchanged drug; hepatic metabolism: 20% (glucuronidation); fecal: 10%.
Renal: 70% unchanged; biliary/fecal: 30% as metabolites
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic